162 related articles for article (PubMed ID: 37350119)
1. MERAIODE: A Phase II Redifferentiation Trial with Trametinib and
Leboulleux S; Benisvy D; Taieb D; Attard M; Bournaud C; Terroir-Cassou-Mounat M; Lacroix L; Anizan N; Schiazza A; Garcia ME; Ghuzlan AA; Lamartina L; Schlumberger M; Godbert Y; Borget I
Thyroid; 2023 Sep; 33(9):1124-1129. PubMed ID: 37350119
[No Abstract] [Full Text] [Related]
2. Pharmacokinetics/Pharmacodynamics of Dabrafenib and Trametinib for Redifferentiation and Treatment of Radioactive Iodine-Resistant Mutated Advanced Differentiated Thyroid Cancer.
Balakirouchenane D; Seban R; Groussin L; Puszkiel A; Cottereau AS; Clerc J; Vidal M; Goldwasser F; Arrondeau J; Blanchet B; Huillard O
Thyroid; 2023 Nov; 33(11):1327-1338. PubMed ID: 37725566
[No Abstract] [Full Text] [Related]
3. A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer.
Leboulleux S; Do Cao C; Zerdoud S; Attard M; Bournaud C; Lacroix L; Benisvy D; Taïeb D; Bardet S; Terroir-Cassou-Mounat M; Anizan N; Bouvier-Morel E; Lamartina L; Lion G; Betrian S; Sajous C; Schiazza A; Garcia ME; Ciappuccini R; Schlumberger M; Al Ghuzlan A; Godbert Y; Borget I
Clin Cancer Res; 2023 Jul; 29(13):2401-2409. PubMed ID: 37074727
[TBL] [Abstract][Full Text] [Related]
4. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
[No Abstract] [Full Text] [Related]
5. Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions.
Dadu R; Cabanillas ME
Minerva Endocrinol; 2012 Dec; 37(4):335-56. PubMed ID: 23235190
[TBL] [Abstract][Full Text] [Related]
6. A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer.
Short SC; Suovuori A; Cook G; Vivian G; Harmer C
Clin Oncol (R Coll Radiol); 2004 Dec; 16(8):569-74. PubMed ID: 15630851
[TBL] [Abstract][Full Text] [Related]
7. Novel Therapeutics for Advanced Differentiated Thyroid Cancer.
Lieberman L; Worden F
Endocrinol Metab Clin North Am; 2022 Jun; 51(2):367-378. PubMed ID: 35662446
[TBL] [Abstract][Full Text] [Related]
8. Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study.
Weber M; Kersting D; Riemann B; Brandenburg T; Führer-Sakel D; Grünwald F; Kreissl MC; Dralle H; Weber F; Schmid KW; Herrmann K; Jentzen W; Grafe H; Rischpler C; Theurer S; Bockisch A; Nagarajah J; Fendler WP
Clin Cancer Res; 2022 Oct; 28(19):4194-4202. PubMed ID: 35594174
[TBL] [Abstract][Full Text] [Related]
9. Advances in the molecular mechanism and targeted therapy of radioactive-iodine refractory differentiated thyroid cancer.
Zhang L; Li Z; Zhang M; Zou H; Bai Y; Liu Y; Lv J; Lv L; Liu P; Deng Z; Liu C
Med Oncol; 2023 Jul; 40(9):258. PubMed ID: 37524925
[TBL] [Abstract][Full Text] [Related]
10. Perspective: The Molecular Landscape of Radioactive Iodine Refractory Differentiated Thyroid Cancer and Poorly Differentiated Thyroid Cancer.
Shobab L; Wartofsky L
Thyroid; 2023 Feb; 33(2):138-142. PubMed ID: 36345225
[No Abstract] [Full Text] [Related]
11. Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
Sherman EJ; Dunn LA; Ho AL; Baxi SS; Ghossein RA; Fury MG; Haque S; Sima CS; Cullen G; Fagin JA; Pfister DG
Cancer; 2017 Nov; 123(21):4114-4121. PubMed ID: 28662274
[TBL] [Abstract][Full Text] [Related]
12. Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy.
Wadsley J; Ainsworth G; Coulson AB; Garcez K; Moss L; Newbold K; Farnell K; Swain J; Howard H; Beasley M; Weaver A; Wood K; Marshall J; Griffin M; Pascoe A; Du Y; Taprogge J; Flux G; Brown S
Thyroid; 2023 Sep; 33(9):1119-1123. PubMed ID: 37565288
[No Abstract] [Full Text] [Related]
13. Emerging drugs for the treatment of radioactive iodine refractory papillary thyroid cancer.
Leboulleux S; Lamartina L; Hadoux J; Baudin E; Schlumberger M
Expert Opin Investig Drugs; 2022 Jul; 31(7):669-679. PubMed ID: 35522027
[TBL] [Abstract][Full Text] [Related]
14. Clinical, Pathological, and Molecular Profiling of Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Shobab L; Gomes-Lima C; Zeymo A; Feldman R; Jonklaas J; Wartofsky L; Burman KD
Thyroid; 2019 Sep; 29(9):1262-1268. PubMed ID: 31319763
[No Abstract] [Full Text] [Related]
15. Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer.
Brose MS; Nutting CM; Sherman SI; Shong YK; Smit JW; Reike G; Chung J; Kalmus J; Kappeler C; Schlumberger M
BMC Cancer; 2011 Aug; 11():349. PubMed ID: 21834960
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS.
Oh JM; Ahn BC
Theranostics; 2021; 11(13):6251-6277. PubMed ID: 33995657
[TBL] [Abstract][Full Text] [Related]
17. Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation.
Fleeman N; Houten R; Bagust A; Richardson M; Beale S; Boland A; Dundar Y; Greenhalgh J; Hounsome J; Duarte R; Shenoy A
Health Technol Assess; 2020 Jan; 24(2):1-180. PubMed ID: 31931920
[TBL] [Abstract][Full Text] [Related]
18. Donafenib in Progressive Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Results of a Randomized, Multicenter Phase II Trial.
Lin YS; Yang H; Ding Y; Cheng YZ; Shi F; Tan J; Deng ZY; Chen ZD; Wang RF; Ji QH; Huang R; Li LF
Thyroid; 2021 Apr; 31(4):607-615. PubMed ID: 32907500
[No Abstract] [Full Text] [Related]
19. Definition and management of radioactive iodine-refractory differentiated thyroid cancer.
Schlumberger M; Brose M; Elisei R; Leboulleux S; Luster M; Pitoia F; Pacini F
Lancet Diabetes Endocrinol; 2014 May; 2(5):356-8. PubMed ID: 24795243
[No Abstract] [Full Text] [Related]
20. Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine refractory differentiated thyroid cancer.
Tuttle RM; Brose MS; Grande E; Kim SW; Tahara M; Sabra MM
Best Pract Res Clin Endocrinol Metab; 2017 Jun; 31(3):295-305. PubMed ID: 28911726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
